BioPharmSignal logoBioPharmSignal

Biotech News

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Lixte Biotechnology Holdings (LIXT)Lixte Biotechnology HoldingsConference / presentation

LIXT (LIXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lixt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

LIXTLixte Biotechnology Holdings2026-06-18 12:30 EST

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTLixte Biotechnology Holdings2026-06-12 12:30 EST

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

View all latest news

Lixte Biotechnology Holdings

PP2A Inhibition in Cancer LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug. LB-100 LB-100 is a first-in-class clinical PP2A inhibitor that has shown...

Recent company news

LIXTLixte Biotechnology Holdings2026-08-19 12:30 EST

NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System

LIXTLixte Biotechnology Holdings2026-08-14 12:35 EST

NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE

LIXTLixte Biotechnology Holdings2026-07-31 12:30 EST

NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange

LIXTLixte Biotechnology Holdings2026-07-29 12:30 EST

NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative

LIXTLixte Biotechnology Holdings2026-07-15 12:30 EST

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

Stock data

Close
7.21 USD
Market cap
87.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States